Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Financials early next week?
View:
Post by Eoganacht on Aug 23, 2022 2:30pm

Financials early next week?

Last year the financials came out on Monday, Aug. 30
In 2020 they came out on Friday, August 28

So probably next Monday the 29th or Tuesday the 30th...

All eyes will be on results for those 11 pending at 270 days...
Comment by 99942Apophis on Aug 23, 2022 3:10pm
Eoganacht wrote Last year the financials came out on Monday, Aug. 30 In 2020 they came out on Friday, August 28 So probably next Monday the 29th or Tuesday the 30th... All eyes will be on results for those 11 pending at 270 days... To be clear the 270 day update will be on 24 patients per official news release, patient 25 should also clear as #25 probably received  treatment  ...more  
Comment by Legit62 on Aug 23, 2022 3:13pm
Save me a glass
Comment by Oilminerdeluxe on Aug 23, 2022 3:24pm
He he, don't sell the skin before the bear is shot! But hopefully there will be cause of celebration next update. Would be sweet indeed. 
Comment by Eoganacht on Aug 23, 2022 4:17pm
Hi 99942Apophis - I think 30 patients should reach 270 days by the end of August. From the Nov. 29 2021 MD&A: "As of November 29, 2021, (270 days ago) Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients..." Theralase planned to treat patient 25 in 3Q2021 ...more  
Comment by ScienceFirst on Aug 23, 2022 4:27pm
Eoganacht... Nice input. If we remove the first 12 undertreated patients from those 30 ones, we would have 60% of those 30 ones that would belong to the optimized group.   If TLT could break us down their data, we could potentially see a trend for this optimized group 60% into the 450-day DR target, giving us a much more predictable picture of where we could land as we add more patients ...more  
Comment by gebremeskel on Aug 23, 2022 5:48pm
Hi ScienceFirst - here's the 270 day table from the May 30 MD&A:   270 Days CR 10 PR 2 NR 14 Pending 15 Total 41 If you remove the 3 phase 1 patients you get   270 Days CR 8  ...more  
Comment by ScienceFirst on Aug 23, 2022 6:18pm
Thanks Gebremerkel.
Comment by 99942Apophis on Aug 23, 2022 4:52pm
Yes Eoganacht and in my post I stated " per official news release "  sure because of the nature of importance of this release it would be very welcomed to see current calendar on patients.  The upcoming Q2 release might be financial only to Q2 and patient data to current time-line if so that would be great. Either way this data will definitely give us a clear picture.  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250